NCT02812433View on ClinicalTrials.gov

Sildenafil Administration to Treat Neonatal Encephalopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2022

Conditions
Neonatal Encephalopathy
Interventions
DRUG

Sildenafil

sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life

DRUG

Ora-Blend

Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life

Trial Locations (1)

H3C1H3

Montreal Children's Hospital, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02812433 - Sildenafil Administration to Treat Neonatal Encephalopathy | Biotech Hunter | Biotech Hunter